Daewoong Pharmaceutical (India) Private Limited, a active foreign private limited company, was established on 30 November 2012 in Hyderabad, Telangana, India. Engaging in drug formulation & development within the manufacturing sector, it holds CIN: U24232TG2012FTC084511. Registered under ROC Roc Hyderabad. it is unlisted. It has an authorized capital of ₹2.90 Cr and a paid-up capital of ₹2.86 Cr.
It upholds a compliant status. Employing 23 professional, Its leadership includes Neelima Aryasomayajula (Additional Director), Gwan Young Kim (Director), Chung Hyun Song (Director). Past directors included Insuk Oh, Minsuk Lee, Yong Hae Han. Its latest AGM occurred on 30 September 2025, with the balance sheet filed on 31 March 2025. It is based at Plot No.5A, A.P.I.I.C Kukatpally, Hyderabad, Telangana, 500072.
U24232TG2012FTC084511
084511
30 November 2012
₹2.90 Cr
₹2.86 Cr
Roc Hyderabad
Unlisted
Active
Explore comprehensive insights into Daewoong Pharmaceutical (India) Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Neelima Aryasomayajula | Additional Director | 21 May 2024 | Current |
| Gwan Young Kim | Director | 09 Apr 2018 | Current |
| Chung Hyun Song | Director | 08 Feb 2016 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Director | 28 Jul 2017 | Past |
| Pramod Abcsdd | Director | 28 Jul 2017 | Past |
| Pramod Abcsdd | Director | 17 May 2018 | Past |
| Pramod Abcsdd | Additional Director | 21 Sep 2018 | Past |
| Pramod Abcsdd | Director | 07 Nov 2017 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Daewoong Pharmaceutical (India) Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 2.9% increase. The company also saw a substantial fall in profitability, with a 21.89% decrease in profit. The company's net worth Soared by an impressive increase of 10.49%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2023, Daewoong Pharmaceutical (India) had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
There are no open charges registered against the company as per our records.
Daewoong Pharmaceutical (India) has a workforce of 23 employees as of Mar 30, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Gain comprehensive insights into the Deals and Valuation data of Daewoong Pharmaceutical (India), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Daewoong Pharmaceutical (India)'s trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Progress on Daewoong Pharmaceutical (India) Private Limited last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records. was documented.
Progress on Daewoong Pharmaceutical (India) Private Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Hyderabad. was documented.
Progress on Neelima Aryasomayajula was appointed as a Additional Director was appointed as a Additional Director on 21 May 2024 & has been associated with this company since 1 year 7 months . was documented.
Gwan Young Kim was appointed as a Director was appointed as a Director on 09 Apr 2018 & has been associated with this company since 7 years 8 months . was recorded as a recent event.
The activity Chung Hyun Song was appointed as a Director was appointed as a Director on 08 Feb 2016 & has been associated with this company since 9 years 10 months . was completed.
Daewoong Pharmaceutical (India) Private Limited was registered on 30 Nov 2012 with Roc Hyderabad & aged 13 years 22 days as per MCA records. was recorded as a recent event.
No. 1 pharmaceutical company in Morocco in the field of digestive health .
The CIN of Daewoong Pharmaceutical (India) Private Limited is U24232TG2012FTC084511.
Daewoong Pharmaceutical (India) Private Limited is headquartered at Plot No.5A, A.P.I.I.C Kukatpally, Hyderabad, Telangana, 500072.
Daewoong Pharmaceutical (India) Private Limited was incorporated on 30 November 2012.
The current directors of Daewoong Pharmaceutical (India) Private Limited are
The primary industry of Daewoong Pharmaceutical (India) Private Limited is Manufacturing.
Daewoong Pharmaceutical (India) Private Limited is unlisted.
The authorized capital of Daewoong Pharmaceutical (India) Private Limited is ₹2.90 Cr, and the paid-up capital is ₹2.86 Cr.
The compliance status of Daewoong Pharmaceutical (India) Private Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX